PRLog (Press Release)
- Jan. 7, 2013 -
BioAsia, Asia’s biggest technology and bio-business platform for Biotechnology and Life sciences announced that Spain will be the Country Partner and GVK Biosciences will be the principal industry sponsor for the 10th edition of BioAsia – BioAsia 2013. Taking place at the Hyderabad International Convention Centre (HICC), Hyderabad from 28th to 30th January 2013, this much-awaited and most comprehensive life sciences dynamic global forum will witness the best convergence under its cutting-edge theme of TECHNOLOGIES.BUSINESS.NEXT.
BioAsia 2013 has also joined hands with Victoria (Australia) which is the International State Partner for the event this year. These country and state level partnerships will open up and enhance the bilateral trade in these regions in addition to fostering scientific and technological collaborations.
The 10th edition of this leading industry event has also received tremendous response from the industry with Natco, Lonza, Mayar Biotech joining as the Industry Co-Host.
Department of Biotechnology;
Department of Pharmaceuticals;
Indian Council of Medical Research; Defense Research & Development Organisation (DRDO) from the Government of India have joined hands with BioAsia 2013 like each year. Commenting on the event Mr. S. Raghavan, Joint Secretary, Department of Biotechnology, GoI – the apex body for Biotechnology in the Country said “BioAsia is playing an important role in mobilizing investments into the biotechnology arena of the country. It has emerged as a prominent platform for facilitating investments, exploring technology opportunities as well as research and innovations for the sector. Dept of Biotechnology is extremely happy to support this global event. The 10th Edition of BioAsia has attracted a wider participation from across the industry that will culminate into more wholistic discussion, debate and decision making giving the much needed momentum to the growth of the biotech industry.”
Commenting on the developments, Mr. Shakthi M Nagappan, CEO, BioAsia, said “We are delighted with the enthusiastic response from various regions and industry stalwarts like to be part of BioAsia 2013. Our partners, sponsors and participants have recognized the incremental value that BioAsia has added to the industry and we are confident to carry forward the momentum with our tenth edition which is all set to bring excellent opportunities to network with potential business prospects across geographies and deliberate on the growth drivers of future”. Sponsors’ Comments:
Commenting on the continued partnership with BioAsia, Mr. Manni Kantipudi, CEO, GVK Biosciences said “I have seen BioAsia grow year over year for the last 5 years. It has evolved to be one of the top conferences in India for Bio-Pharmaceutical companies and offers a good platform for Industry/Government interaction. Today, BioAsia has a global reach and has participants from over 50 countries. GVK BIO is pleased to be the Principal Sponsors for BioAsia 2013”
Commenting further, Dr. AKS Bhujangara Rao, President (R&D), Natco Pharma said “Bio-Asia has been the ‘mouth- piece’ of the Indian Life Sciences activities bridging the state of art academic inventions the Industry’s emerging capabilities and the societal health care needs. The Indian Bio-Pharma Industry is grateful to Bio-Asia for its initiatives over the years”
“BioAsia provides the perfect platform to target the right persons at the right level. We are very pleased to partner with BioAsia and believe that it’s a forum to launch and create visibility for our Indian Subsidiary” said Mr. Vikas Bhargava, Director (India Operations), IKS International"BioAsia as a platform has been evolving consistently each year adding new dimensions to spur the expansion of the industry with the growing global participation. We see a great potential in this event as it has and continue to help Biopharma and Life sciences industry to prosper and grow to new heights" Mr. Deepak Sood, Business Director – South Asia & Middle East, Lonza Biosciences.
BioAsia 2013, hosted by Government of Andhra Pradesh with the support FABA and Pharmexcil, is going to be the window to the future of Lifesciences. BioAsia 2013 will deliver the ultimate platform to anticipate the next required shift in perspective, vision and innovation in Lifesciences.About BioAsia:
BioAsia is born with a vision to enhance, enrich and encourage newer innovations, path-breaking discoveries and effective solutions in the biotechnology industry by offering a vibrant global platform for convergence of the key stakeholders - Biotech & Biopharma Companies, research institutions, academia, investors, service providers, policy makers, regulators and analysts. BioAsia is focused in its efforts - to drive the growth of the industry by enabling an effective environment for fostering collaborations, JV’s M&A’s;
ensure knowledge and experience sharing by global industry players to benefit all stakeholders;
promote innovations and initiatives through appropriate awards and recognitions;
play a pivotal role in advocating issues to the policy makers and chartering the road-map of bio-technology. BioAsia is a dynamic platform for companies -to exhibit, launch and showcase their unique strengths, products and services. BioAsia is playing the role of a key catalyst in mobilizing all elements that are required to drive the growth of the emerging industry of Biotechnology as well as optimize the immense business potential of biotech. On a larger level, BioAsia is working to drive a global transformation from the treatment of illness to wellness.About FABA (Federation of Asian Biotech Associations):
The Federation of Asian Biotech Associations [FABA], is a non-profit registered society engaged in various activities related to promoting Biotechnology in Asian countries. FABA, headquartered at Hyderabad made its humble beginning in 2004 and has achieved a significant landmark in creating a common platform for interaction among member countries and discuss the issues of common interest for improving the biotech space including Technology Transfer, resource sharing, business collaborations, Industry-Academia linkage, cross border trade and investments, etc. among its member countries., FABA has a strong network base in 20 Asian countries including China, India, Bangladesh, Malaysia, Philippines, Russia, Kazakhstan, Pakistan, Israel, Iran, Indonesia, Nepal, Japan, South Korea, Singapore, Thailand, Sri Lanka and UAE. Besides, FABA has entered into working understandings with Non-Asian organizations like European Federation of Biotechnology, Biocat (Spain), Maryland India Business Round Table (USA), Bio Industry Park (Italy) and Association of German Biotech companies (Germany), etc.Pharmexcil:
Pharmaceutical Export Promotion Council (Pharmexcil)
was set up by the Ministry of Commerce and Industry, Government of India in 2004 is located at Hyderabad for promotion of pharmaceutical exports from India. Various pharmaceutical products, namely, bulk drugs and its intermediates, formulations, biotech and biological products, herbal products, ayurvedic, unani and homeopathic medicines, diagnostics, surgical, neutraceuticals, collaborative research, contract manufacturing, clinical trials and consultancy, etc. are covered under its purview. Pharmexcil takes up several external trade promotion activities by organizing trade delegations outside India, arranging buyer-seller meetings, international seminars, interactive meetings on exports related issues, make suggestions to Govt. of India on policy issues relating to pharma exports, make representations to Govt. of India and other agencies in India and abroad to get amicable solutions for the common problems of the industry, etc.